Evaluate the Efficacy and Safety of Goofice® (Elobixibat) in Patients With Chronic Constipation

Phase 3

Recruiting

• Conditions: Constipation
• Interventions: Drug: Goofice® Placebo; Drug: Goofice®

• Registration Number: NCT05895877
• Lead Sponsor: Synmosa Biopharma Corp.

Brief Summary

This is a double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of Goofice® in patients with chronic constipation.

Detailed Description

In order to enroll appropriate patients with chronic constipation, a 2-week constipation-related symptom intensity screening period will be established to investigate the number of bowel movements just prior to the study drug treatment initiation. Eligible subjects who fulfill all selection criteria for enrollment will be randomly assigned to receive Goofice® or placebo drug with 2:1 allocation ratio. The study drug will be received once daily approximately 30 minutes before breakfast in the 12-week treatment period. The starting dosing of Goofice® / placebo will be 10 mg (2 tablets) in treatment period. It is allowed to adjust the dosage among 5, 10, and 15 mg after 7 days after treatment initiation, if the dose adjusting criteria are met depending on symptoms. After treatment period, subjects will be followed up for 4 weeks to observe the effect of discontinuing treatment.

Study Timeline

• Study Start: 2021-12-21
• Status Verified: 2022-09
• Study First Submitted: 2022-09-23
• Study First Submitted QC: 2023-05-29
• Last Update Submitted: 2023-05-29
• Study First Posted: 2023-06-09
• Last Update Posted: 2023-06-09
• Primary Completion: 2023-09-30
• Study Completion: 2023-09-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 351

Inclusion Criteria

• At provisional enrollment

1. Men or women ≥ 20 years of age.

2. Include 2 or more of the following during the last 3 months with symptom onset of at least 6 months:

   1. Straining during more than 25% of bowel movements (BMs);)

   2. Lumpy or hard stools in 25% of BMs;

   3. Sensation of incomplete evacuation in more than 25% of all BMs;

   4. Sensation of anorectal blockage or obstruction in more than 25% of BMs;

   5. Manual maneuvers required in more than 25% of BMs;

   6. Fewer than 3 BMs per week.

      In addition to having at least 2 of the above criteria, the following must also apply:

   a. Loose stools are rarely present without the use of laxatives; b. Insufficient criteria for irritable bowel syndrome (IBS).

3. Ability to provide written consent. - At time of enrollment

4. A total of SBM frequencies < 6 times during the 2-week screening period.

Exclusion Criteria

• At provisional enrollment

  1. Known or suspected allergy to components in elobixibat.

  2. Known or suspected organic constipation.

  3. Known or suspected symptomatic or drug-induced constipation.

  4. Known or suspected slow colon transit type constipation.

  5. Known or suspected excretory disorder constipation.

  6. Currently have or history of gastrointestinal obstruction.

  7. Currently have or history of abdominal hernia.

  8. History of laparotomy other than simple appendectomy.

  9. History of cholecystectomy or surgical or endoscopic intervention related to papillotomy.

  10. Subjects in whom the dosage regimens of medications, of which changing the dosage regimens is prohibited, will be changed after the day of informed consent.

  11. Cannot use the rescue medication (bisacodyl suppositories 10 mg).

  12. Pregnant, lactating or potentially pregnant women, women who wish to become pregnant from the time of the informed consent to the last observation/test point, or women who do not agree to use appropriate birth control methods. The acceptable effective contraception methods include: a. Male or female sterilization, implant, or intrauterine device; b. Injectable, pill, patch, ring plus one barrier method*; c. Two combined barrier methods*.

      • Effective barrier methods are diaphragm, male or female condoms, sponge, or spermicides (creams or gels that contain a chemical to kill sperm).

  13. Anemia, defined as hemoglobin ≤ 10 g/dL.

  14. Concurrent serious renal disease (creatinine ≥ 2.00 mg/dL) or liver disease (total bilirubin ≥ 3.0 mg/dL, or aspartate aminotransferase(AST) or alanine transaminase(ALT) ≥ 100 U/L).

  15. Concurrent clinical significant heart disease, including uncontrolled hypertension, arrhythmia, or heart failure.

  16. History of serious drug-induced allergy needs emergent medical intervention, such as anaphylaxis, angioedema, generalized urticaria or bronchospasm.

  17. Subjects have a history of cancer (other than basal cell or squamous cell carcinoma of the skin) unless the malignancy has been in a complete remission without maintenance chemotherapy for ≥ 5 years prior to the Screening visit.

  18. Subjects who are taking part in another clinical study, or subjects who take part in another clinical study within 12 weeks prior to the day of informed consent.

  19. Loss of weight greater than 5 kg one month before screening visit.

  20. Determined by the investigator to be not suitable for the conduct of the study for any other reasons.

  21. Subjects have a barium enema within 7 days of the Screening Visit.

• At time of enrollment

  22. Subjects have a clinically significant finding on colonoscopy performed as required in accordance with the American Gastroenterological Association (AGA) guidelines (within AGA time frames). If polyps are found and biopsied, pathology must be reviewed and must be negative for cancer before the subject may be enrolled in the study. 23. Used the rescue medication (bisacodyl suppositories 10 mg) at least 6 times during the 2-week screening period or subjects who used the rescue medication at least 3 times in Week -1 of the screening period. 24. Used the rescue medication for less than 72 hours after bowel movement during the 2-week screening period. 25. Mushy stool or watery stool (Bristol Stool Form Scale type 6 or 7) in SBM during the 2-week screening period. 26. Used prohibited medications/therapies during the 2-week screening period

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Goofice® Placebo	Goofice® Placebo	Active ingredient/Excipients: The placebo drug is identical in appearance to the Goofice ® tablet with the same excipient ingredients, but without the active compound. Dosage and Frequency: Once daily before breakfast. The dosage and frequency is the same as active drug
Goofice®	Goofice®	Active ingredient: Elobixibat 5mg/tab Dosage and Frequency: Once daily before breakfast. The starting dose is total 10 mg of Goofice® (2 tablets). After 7 days of the start of the study treatment, the dosage may be adjusted according to symptoms among the dose levels of 5, 10, and 15 mg.However, the maximum daily dose is 15 mg (3 tablets).

Primary Outcome Measures

Name	Time	Method
Overall Complete spontaneous bowel movement(CSBM) responder rate during 12 weeks treatment	12 weeks	* An overall CSBM responder is a subject who is a weekly CSBM responder for at least 9 of the 12 treatment weeks, including at least 3 of the last 4 treatment weeks.; * A weekly CSBM responder will be defined as a subject with CSBM frequency of ≥ 3 times and CSBM frequency improved by ≥ 1 time from Week -1 of the screening period.; * SBM is defined as defecation without laxative drug/enema or stool extraction. CSBM is defined as SBM without sensation of incomplete evacuation. In this study, when subjects used laxative drug at the day before initiation of screening period or rescue medication after initiation of screening period, defecation within 24 hours after the use of these medications will be not deemed as SBM or CSBM.

Secondary Outcome Measures

Name	Time	Method
Efficacy endpoint - SBM frequency	12 weeks	- Changes in SBM frequency from screening period Week -1 at each week.
Efficacy endpoint - CSBM frequency	12 weeks	- Changes in CSBM frequency from screening period Week -1 at each week.
Efficacy endpoint - Complete spontaneous bowel movement (CSBM) responder rate at Week 12	12 weeks	- A responder will be defined as a subject with weekly (Week 12) CSBM frequency of ≥ 3 times and weekly (Week 12) CSBM frequency improved by ≥ 1 time from Week -1 of the screening period.
Efficacy endpoint - Spontaneous bowel movement (SBM) responder rate at Week 12	12 weeks	- A responder will be defined as a subject with weekly (Week 12) SBM frequency of ≥3 times and weekly (Week 12) SBM frequency improved by ≥ 1 time from Week -1 of the screening period.
Exploratory endpoint - Patient Assessment of Constipation Quality of Life (PAC-QoL)	12 weeks	- Each item of the 28-item questionnaire (Appendix 1) is scored on a 5-point Likert-type scale from 0 to 4, with (0 = none/not at all, 1 = a little bit/a little bit of the time, 2 = moderately/some of the time, 3 = quite a bit/most of the time, 4 = extremely/all the time). Scores are reported overall and for each of the four subscales (physical discomfort, psychosocial discomfort, worries and concerns, and satisfaction). An improvement (reduction) of ≥1 point in PAC-QoL score are considered clinically significant based on previous validation studies.
Efficacy endpoint - SBM and CSBM responder rate	4 weeks	- Changes of SBM and CSBM responder rate during follow-up period.
Efficacy endpoint - Mean stool consistency by Bristol Stool Form Scale	12 weeks	- The stool consistency is assessed based on the Bristol Stool Form Scale on a 7-grade scale.; Grade / Interpretation; 1. / Separate hard lumps, like nuts (hard to pass); 2. / Sausage shaped, but lumpy; 3. / Like a sausage, but with cracks on its surface; 4. / Like a sausage or snake, smooth and soft; 5. / Soft blobs with clear cut edges (passed easily); 6. / Fluffy pieces with ragged edges, a mushy stool; 7. / Watery, no solid pieces, entirely liquid Mean stool consistency as measured at Week -1 and each treatment Week.
Exploratory endpoint - Patient Assessment of Constipation Symptoms (PAC-SYM) scores	12 weeks	- Symptom scores are evaluated using the PAC-SYM questionnaire, a validated, 12-item, Patient-reported outcome (PRO) instrument with abdominal, stool and rectal symptom subscales. Each item of the PAC-SYM is scored on a 5-point Likert-type scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe), with higher scores indicating greater symptom severity. An improvement (reduction) of ≥1 point in PAC-SYM score is considered clinically significant based on previous validation studies.

Trial Locations

Locations (1)

National Taiwan University Hospital Clinical Trial Center; 🇨🇳 Taipei, Taiwan